ADHD Market to Reach Nearly $10 Billion by 2020
The Attention-Deficit Hyperactivity Disorder (ADHD) therapeutics market value will rise from $6.9 billion in 2013 to $9.9 billion by 2020, with broadening diagnostic criteria a key driver of growth, according to GBI Research.
The Attention-Deficit Hyperactivity Disorder (ADHD) therapeutics market value will rise from $6.9 billion in 2013 to $9.9 billion by 2020, with broadening diagnostic criteria a key driver of growth, according to GBI Research.
The company’s new report states that the increase - which represents a Compound Annual Growth Rate (CAGR) of 5.3% and relates to eight major markets (US, UK, France, Germany, Spain, Italy, Japan and Canada) - will occur fastest in Japan, due to the country’s high ADHD prevalence.Diagnosis rates are currently low outside of the US as the disorder is still treated with considerable skepticism, says GBI Research analyst Dale Prior. But this trend is expected to change over the coming decade because of an increased recognition of adult ADHD.
The fifth edition of The Diagnostic and Statistical Manual of Mental Disorders, published last year, broadened the diagnostic criteria for ADHD, recognizing that impairment from symptoms of the disorder may develop in later life.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
